The PI(3)K-Akt-mTORC1 pathway is a highly dynamic network that is balanced and stabilized by a number of feedback inhibition loops 1, 2 . Specifically, activation of mTORC1 has been
shown to lead to the inhibition of its upstream growth factor signalling. Activation of the growth factor receptors is triggered by the binding of their cognate ligands in the extracellular space. However, whether secreted proteins contribute to the mTORC1-dependent feedback loops remains unclear. We found that cells with hyperactive mTORC1 secrete a protein that potently inhibits the function of IGF-1. Using a large-scale, unbiased quantitative proteomic platform, we comprehensively characterized the rapamycin-sensitive secretome in TSC2
−/− mouse embryonic fibroblasts, and identified IGFBP5 as a secreted, mTORC1 downstream effector protein. IGFBP5 is a direct transcriptional target of HIF1, which itself is a known mTORC1 target 3 . IGFBP5 is a potent inhibitor of both the signalling and functional outputs of IGF-1. Once secreted, IGFBP5 cooperates with intracellular branches of the feedback mechanisms to block the activation of IGF-1 signalling. Finally, IGFBP5 is a potential tumour suppressor, and the proliferation of IGFBP5-mutated cancer cells is selectively blocked by IGF-1R inhibitors.
The evolutionarily conserved serine/threonine kinase mTOR (mechanistic target of rapamycin) is a central regulator of cell growth and proliferation. mTOR is distributed into two complexes, mTORC1 and mTORC2. The upstream inputs regulating mTORC1 have been extensively characterized. Multiple signals (for example, from growth factors and tumour-promoting phorbol esters) converge on the heterodimeric TSC1/2 (tuberous sclerosis complex) protein complex to regulate the activation of mTORC1, in a Rheb-dependent manner 1, 2 . In addition, mTORC1 activity is also under the tight control of cellular amino acid levels 4 . The best-known mTORC1 substrates are the eIF4E-binding proteins (4EBPs) and the ribosomal protein S6 kinases (S6K), both of which are known to regulate protein synthesis 5 . Recently, we and others have used large-scale quantitative mass spectrometry experiments to comprehensively characterize the mTORC1-regulated phosphoproteome [6] [7] [8] . These studies measured, on a global level, the changes in protein phosphorylation on rapamycin treatment, and in so doing, identified additional mTORC1 substrates (for example, growth factor receptor-bound protein 10, GRB10; refs 6, 8) .
Downstream effector proteins of mTORC1 are known to communicate with its upstream regulators (for example, receptor tyrosine kinases, RTKs), through various feedback loops 9 . These feedback mechanisms play a critical role in maintaining the stability of the entire network. They also have great significance in a variety of diseases. In particular, mTORC1 is hyperactivated in many human cancers, as a result of mutations of upstream oncogenes and tumour suppressors (for example, PI3K, PTEN, Akt, TSC1/2, and so on) 2 , or mTOR itself 10 . In most of the cases, rapamycin or mTOR kinase inhibitors, however, fail to kill tumour cells 11 . Recent studies have suggested multiple mechanisms of rapamycin resistance. For example, tumours could develop mTOR mutations that prevent the binding of rapamycin to the protein by means of steric hindrance 12 . In addition, rapamycin resistance could also stem from the relief of mTORC1-mediated feedback inhibition loops 2 . Specifically, mTORC1 inhibition could activate growth factor signalling, providing an alternative means of promoting cell survival and proliferation, under these mTORC1-repressed conditions 13 . A number of studies have demonstrated that the feedback mechanisms involve mTORC1/S6K targeting growth factor receptors Figure 1 Cells with hyperactivated mTORC1 secrete a protein factor(s) that blocks IGF-1 signalling. (a) CM (conditioned media) was collected from TSC2 +/+ MEFs (CM +/+ ) or TSC2 −/− MEFs (CM −/− ), mixed with the indicated growth factor, and then incubated with wild-type MEFs (designated as 'recipient cells') for 10 min. CM that was not mixed with any growth factors is indicated as 'starve'. CM was also collected from TSC2 −/− MEFs that had been treated with 20 nM rapamycin for 24 h (CM −/− Rapa). As a control experiment, CM from TSC2 −/− cells were collected first, and then mixed with rapamycin (CM −/− Rapa mock). For site-specific phosphorylation, pAkt(S473) levels were analysed. Growth factor concentrations are: insulin, 100 nM; IGF-1, 40 ng ml −1 ; PDGF, 50 ng ml −1 ; EGF, 50 ng ml −1 ; and HGF, 50 ng ml −1 . WCL, whole-cell lysate. (b) CM from TSC2 −/− MEFs is able to block the activation of the IGF-1 signalling pathway. Experiments were performed as in a. pIGF-1R(Y1135/1136), pAkt(S473) and pERK(T202/Y204) levels were analysed. (c) A general schematic of the quantitative secretomic platform. SCX-RP-HPLC, strong-cation-exchange reversed-phase high-performance liquid chromatography. (d) Ratio distribution of the identified peptides (a total of 61,920 from 3,099 proteins). Ratio (control/rapamycin-treated) distribution of these peptides is shown on a log 2 scale. Light and heavy lysates were also subject to immunoblotting analysis for pS6K(T389) levels. (e) Extracted ion chromatogram of the light (rapamycin-treated, blue) and heavy (control, yellow) ions of an IGFBP5 peptide (HMEASLQEFK). (f) CM from TSC2 −/− MEFs, but not TSC2 +/+ MEFs, contains high levels of IGFBP5. Cells were starved for 24 h, after which CM was collected. When indicated, cells were also treated with rapamycin (20 nM for 24 h). CM and WCL of these cells were analysed by immunoblotting for pS6K(T389) levels. (g) IGFBP5 expression is regulated by mTORC1 at the transcription level. Total RNA was extracted from TSC2 +/+ MEFs, TSC2 −/− MEFs, or TSC2 −/− MEFs that had been treated with 20 nM rapamycin for 24 h, and was analysed. (h) Treatment of TSC2 −/− MEFs by rapamycin (20 nM), Ku0063794 (1 µM) and NVP-BEZ235 (500 nM), but not an S6K inhibitor (PF-4708671, 10 µM), led to downregulation of IGFBP5 in CM. For site-specific phosphorylation, pS6K(T389) and pS6(S235/236) levels were analysed. Unprocessed original scans of blots are shown in Supplementary Fig. 6 .
proteins contribute to mTORC1-dependent feedback mechanisms is unknown.
To address this question, we serum-starved a pair of isogenic TSC2 +/+ and TSC2 −/− mouse embryonic fibroblasts (MEFs) in DMEM for 24 h, and collected their conditioned media (CM). Loss of TSC2 disengages mTORC1 from the upstream inputs, resulting in its constitutive activation, even in serum-free media 8, 20 . As a result, these cells are resistant to serum deprivation-induced apoptosis ( Supplementary Fig. 1A ). They also possess potent mTORC1-dependent feedback loops ( Supplementary Fig. 1B) . We mixed the corresponding CM with various growth factors, including insulin, IGF-1, PDGF, EGF and HGF. These CM samples were then incubated with separate plates of wild-type MEFs (Fig. 1a) . We found that IGF-1 was able to activate IGF-1R and Akt in recipient cells only when it was mixed with CM from TSC2 +/+ cells, but not with that from TSC2 −/− cells (Fig. 1a,b) . Activity of the other growth factors was not affected by TSC2 −/− CM. Remarkably, this IGF-1-inhibitory activity was abrogated in CM from TSC2 −/− cells that had been treated with rapamycin for 24 h (Fig. 1a) . Here, because this CM contained rapamycin, there was also a possibility that the observed restoration of IGF-1 signalling was a direct effect of rapamycin on the recipient cells. We performed control experiments where we collected CM from TSC2 −/− cells, and then mixed it with rapamycin. We found that this mock-treatment media retained the ability to inhibit IGF-1 (Fig. 1a) . The simplest hypothesis that is consistent with these observations would be that cells with hyperactive mTORC1 secrete a factor(s) that is able to block the function of IGF-1.
TSC2 −/− CM that had been heated to 95
• C completely lost its ability to inhibit IGF-1, suggesting that this factor might be a protein ( Supplementary Fig. 1C ). This experiment also ruled out the possibility that the observed effect was because mTORC1 activation inhibits the accumulation of an IGF-1-potentiating protein (in which case, heating the CM from TSC2 −/− cells would not affect its ability to modulate IGF-1 signalling).
We sought to identify this mTORC1-regulated, secreted protein factor(s) that has IGF-1-inhibitory activity. Mass spectrometric analysis of secreted proteins, however, is technically challenging, owing to their often exceedingly low abundances 21 . By coupling multidimensional high-performance liquid chromatography separation with a Velos Pro Orbitrap mass spectrometer, we established a highsensitivity mass spectrometry platform for comprehensive secretomic analysis (Fig. 1c) .
Although uncontrolled activation of mTORC1 is the best studied and the predominant consequence of TSC2 loss, there could be mTORC1-independent functions from TSC2 loss. These functions might also regulate the expression of secreted proteins. We therefore focused on identifying secreted proteins whose expression was altered as a result of rapamycin treatment. We used the SILAC (stable isotope labelling by amino acids in cell culture) approach 8, 22 as the quantification method (Fig. 1c) . Both light and heavy TSC2 −/− MEFs were serum-deprived for 24 h, during which light cells were rapamycin-treated (Fig. 1d) . CM from the light and heavy cells were collected, combined (at a 1:1 ratio at the protein level) and analysed by the above-mentioned quantitative secretomic platform.
From this SILAC CM sample, we identified and quantified a total of 61,920 peptides from 3,099 proteins (peptide false discovery rate = 0.27%; Fig. 1d and Supplementary Fig. 1D and Supplementary Tables 4-7). mTORC1 inhibition leads to a marked change in the secretome. Specifically, 355 and 145 proteins showed a decrease and increase in their abundances, by at least 32-fold, respectively, after rapamycin treatment (Fig. 1d) . For example, the abundance of fibroblast growth factor 21 (FGF21) markedly decreased after rapamycin treatment (Supplementary Fig. 1E ). FGF21 is a secreted hormone whose expression is known to be regulated by mTORC1 (ref. 23 ). The identification of this known mTORC1 downstream target in the extracellular space validates the robustness of our quantitative secretomic approach.
As rapamycin treatment abrogated the expression of the IGF-1-inhibitory protein (Fig. 1a) , we focused our follow-up analysis on proteins whose abundances decreased as a result of mTORC1 inhibition. Gene ontology (cellular compartment) analysis of these proteins showed that they were enriched for extracellular matrix proteins (P = 6.5 × 10 −10 ; Supplementary Fig. 2A ). Intriguingly, one of the enriched molecular function categories was growth factor binding proteins (P = 1.7 × 10 −4 ; Supplementary Fig. 2B ). In particular, the level of IGFBP5 (IGF binding protein 5) decreased markedly (by approximately 68-fold; similar change was found in the replicate SILAC experiment) after rapamycin treatment ( Fig. 1e and Supplementary Fig. 1F ).
IGFBPs are secreted proteins that are known to bind to circulating IGF-1 (ref. 24) . Interestingly, another member of the IGFBP family, IGFBP3, has recently been shown to be regulated by mTORC2 (ref. 25) . We confirmed that TSC2 −/− contained high levels of IGFBP5 at both the protein (in CM) and messenger RNA levels (Fig. 1f,g ). Conversely, this protein was virtually absent in CM from TSC2 +/+ MEFs. To rule out the possibility that this observation is due to artefacts resulting from in vitro culturing of these isogenic cells, we generated TSC2-reconstituted cells by introducing TSC2 back into TSC2 −/− MEFs. Indeed, these 'wild-type' cells also contained undetectable levels of secreted IGFBP5 (Supplementary Fig. 1G ).
Inhibition of mTORC1 in TSC2 −/− MEFs by either rapamycin or mTOR kinase inhibitors (Ku0063794 and NVP-BEZ235; ref. 8) resulted in a marked decrease of IGFBP5 (Fig. 1f-h ). In contrast, treatment of these cells with an S6K inhibitor, PF-4708671 (ref. 26) , had no effect on IGFBP5 levels (Fig. 1h) . These results indicate that mTORC1 itself, rather than S6K, regulates the expression of IGFBP5. mTORC1 also regulates the expression of IGFBP5 in other cell lines (RT-4 and MCF7, Supplementary Fig. 1H,I) .
As the mRNA level of IGFBP5 positively correlated with mTORC1 activity (Fig. 1g) , we reasoned that transcription regulation might contribute to mTORC1-dependent IGFBP5 expression. Several transcription factors are known to function downstream of mTORC1, including sterol regulatory element-binding protein (SREBP), c-Myc and HIF1 (hypoxia-inducible factor 1; refs [27] [28] [29] . HIF1 is of particular interest because it modulates the expression of a number of secreted proteins (for example, VEGF; ref. 30) . Activation of mTORC1 promotes the synthesis of HIF1α, specifically through enhancing the translation of its mRNA that contains long and structured 5 -UTRs (ref. 3) .
Consistent with previous studies 27 , we found that rapamycin treatment markedly lowered the expression of HIF1α and, concomitantly, IGFBP5 in TSC2 −/− MEFs (Fig. 2a) . A similar decrease in IGFBP5 was observed when HIF1α was knocked down using RNAi (RNA interference) in TSC2 −/− MEFs (Fig. 2b,c ) and RT-4 cells (Fig. 2d) . We found that HIF1 was also sufficient for IGFBP5 expression. Specifically, treatment of RT-4 cells with a hypoxia-mimetic agent, CoCl 2 (ref. 30) , led to robust accumulation of HIF1α and IGFBP5 (in CM) (Fig. 2e) . Importantly, co-treatment of CoCl 2 and rapamycin suppressed HIF1α and IGFBP5 expression to levels even lower than CoCl 2 -untreated samples (Fig. 2f,g ), suggesting a dominant effect from mTORC1 inhibition. IGFBP5 expression is no longer sensitive to rapamycin treatment in an ectopic expression system (the construct does not contain the highly structured 5 -UTR of HIF1α), suggesting that the effect of rapamycin on IGFBP5 expression is dependent on mTORC1-mediated translation of HIF1α (Fig. 2h) . To explore whether HIF1 directly regulates the transcription of IGFBP5, we screened a series of pGL4 luciferase reporter constructs harbouring inserts representing different regions of the IGFBP5 gene ( Supplementary Fig. 3 ). We found that the expression of one construct (pGL4-P4-luc) that carries a 300-base-pair (bp; from +2.9 Kb to +3.2 Kb) fragment downstream of the IGFBP5 transcription start site in HEK293T cells led to a marked increase in luciferase activity, when these cells were co-transfected with a pcDNA3-HIF1A plasmid (Fig. 2i ). These data suggest that there could be potential HIFresponsive elements (HREs) in this region of the IGFBP5 gene. Chromatin immunoprecipitation-quantitative PCR (ChIP-qPCR) experiments then confirmed the existence of such HREs (Fig. 2j) .
On the basis of the consensus binding motifs of HIF1 (5 -CGTG-3 ; ref. 31 ), we identified a total of five potential HREs in this region (HRE1-HRE5, Supplementary Fig. 3 ). We found that the deletion of either HRE1 or HRE3 markedly lowered the binding of HIF1 in the luciferase assay. HIF1 completely lost its ability to recognize the IGFBP5 mutant that has been deleted for both HRE1 and HRE3, indicating that these two HREs are the most important sites for HIF1-dependent transcription regulation of IGFBP5 (Fig. 2k) . Taken together, these data demonstrate that HIF1α regulates the transcription of IGFBP5 through directly binding to its HREs.
IGFBP5 is known to bind, with high affinity, to circulating IGFs (ref. 24) . However, it remains controversial whether IGFBP5 impacts IGF-1 signalling in a positive or negative manner. IGFBP5 could block IGF-1 signalling by binding to, and sequestering it from interacting with IGF-1R (ref. 32). On the other side, IGFBP5 might also potentiate the function of IGF-1, presumably by better presenting IGF-1 to IGF-1R (ref. 33) . We found that the addition of IGFBP5 to the media resulted in strong inhibition of IGF-1 signalling in wild-type MEFs (Fig. 3a) . We found that IGFBP5 is also necessary for the IGF-1-inhibitory activity in TSC2 −/− CM. TSC2 −/− MEFs are characterized by a profound 'IGF-1-resistant' state, as indicated by their lack of response to IGF-1 (Fig. 3b) . Intriguingly, depletion of IGFBP5 in TSC2 −/− MEFs greatly sensitizes them to IGF-1 stimulation (Fig. 3b) . We next examined whether IGFBP5 also inhibits the functional outputs of IGF-1. We found that the addition of IGFBP5 to culture media completely blocked IGF-1-induced proliferation of MCF7 cells (Fig. 3c,d) . As IGFBP5 is a secreted protein that functions in the extracellular space, it may also provide a 'non-cell autonomous' mechanism for mTORC1 to regulate the growth and proliferation of adjacent cells. We tested this hypothesis using a co-culture system. Specifically, MCF7 cells were labelled with red florescent protein (DsRed, RFP), and were grown with GFP-labelled TSC2 +/+ or TSC2 −/− MEFs. Interestingly, the proliferation of MCF7 cells was markedly suppressed when they were co-cultured with TSC2 −/− MEFs ( Supplementary Fig. 4A ), an effect that can be ascribed to IGFBP5 (Fig. 3e) .
We investigated whether IGFBP5 can modulate the anti-apoptosis function of IGF-1. We found that IGF-1 could block starvationinduced apoptosis of MCF7 cells, which was reversed when IGFBP5 was present in the media (Fig. 3f) . Furthermore, IGFBP5 also blocked the pro-survival effect of IGF-1 when cells were treated with cytotoxic agents, including staurosporine, etoposide and doxorubicin ( Fig. 3g and Supplementary Fig. 4B,C) .
Activation of mTORC1 triggers a number of feedback loops that converge on, and antagonize IGF-1 signalling 9 . We sought to determine the relative contribution of IGFBP5, compared with the known players in these feedback loops. First, we asked the question of how much of the IGF-1-inhibitory activity in TSC2 −/− CM could be attributed to IGFBP5. We collected CM from TSC2 −/− MEFs with either control or IGFBP5 knockdown, and mixed them with IGF-1, and treated wild-type MEFs. We found that the degree of IGF-1R activation in the recipient cells using the IGFBP5 shRNA TSC2 −/− CM is approximately 85% of that using the TSC2 +/+ CM, indicating that IGFBP5 accounts for a large fraction of the IGF-1-inhibitory activity in TSC2 −/− CM ( Supplementary Fig. 4D ). We next examined, on the whole-cell level, IGF-1 signalling in TSC2 −/− MEFs that were treated with either rapamycin or IGFBP5 shRNA. Both treatments greatly sensitized these cells to IGF-1 stimulation ( Supplementary Fig. 4E) . We, at the same time, did observe a lower pIGF-1R and pAkt level in IGFBP5 shRNA TSC2 −/− MEFs, compared with that in rapamycin-treated GFP shRNA TSC2 −/− MEFs ( Supplementary Fig. 4E ). We then generated TSC2 −/− cells with single knockdown of either GRB10 or IGFBP5, as well as cells with GRB10 and IGFBP5 double knockdown (Fig. 4a) . Compared with rapamycin treatment, knockdown of either GRB10 or IGFBP5 partially recovered IGF-1-dependent Akt activation. However, TSC2
−/− MEFs co-depleted for both GRB10 and IGFBP5 almost completely regained IGF-1 sensitivity (Fig. 4a) . Finally, double knockdown of GRB10 and IGFBP5 also markedly accelerates the proliferation of TSC2 −/− cells, in response to IGF-1 stimulation (Fig. 4b) . We previously showed that GRB10 is a potential tumour suppressor 8 . As IGFBP5 also inhibits the function of IGF-1 (Fig. 4a) Fig. 4c ). We generated mammalian expression constructs (with a carboxy-terminal HA tag) harbouring the individual mutations that have been reported for IGFBP5. We ectopically expressed them in HEK293T cells, collected the corresponding CM, and mixed them with IGF-1. These CM samples were added to wildtype MEFs (Fig. 4d,e) . Intriguingly, half of these cancer-associated IGFBP5 mutants completely lost their IGF-1-inhibitory activity, including the above-mentioned truncation mutations, as well as three additional point mutations (G223R, R236H and V244M; Fig. 4d) .
Hyperactivation of IGF-1 signalling plays a critical role in establishing a transformed phenotype in a number of malignancies 34 . The development of IGF-1R inhibitors, however, have been largely unsuccessful, in part owing to the lack of a viable approach for patient stratification 35 . We reasoned that the loss of IGFBP5 might drive the survival and proliferation of a cancer cell dependent on IGF-1 signalling. This, in turn, might confer their sensitivity to IGF-1R inhibitors. From the COSMIC database, we identified that NCI-H1435, a non-small-cell lung cancer (NSCLC) cell line, harbours a heterozygous IGFBP5 mutation (E202 * ) (Fig. 4f) . Moreover, the CM from this cell line lacks a detectable signal from IGFBP5 ( Supplementary Fig. 5A ), indicating the presence of additional misregulation of this protein. Indeed, the proliferation of NCI-H1435 cells was inhibited by various clinically relevant IGF-1R inhibitors, including BMS-536924 and BMS-754807 (ref. 34) . Conversely, the growth of IGFBP5-WT NSCLC cell lines, including HCC15, A549, NCI-H1693 and HCC4017, was not affected by IGF-1R inhibitors ( Fig. 4g and Supplementary Fig. 5D ). Finally, all of these NSCLC cell lines were resistant to a multi-RTK inhibitor, Sunitinib, which, however, is inactive against IGF-1R (ref. 36 ; Fig. 4g ). The proliferation of an IGFBP5-mutated leukaemia cell line, Molt-4 (K135fs * 13), was also selectively inhibited by IGF-1R inhibitors ( Supplementary  Fig. 5B) . Importantly, the re-expression of IGFBP5 in Molt-4 cells led to their decreased proliferation (Supplementary Fig. 5C ).
In summary, our results indicate that mTORC1 positively regulates the expression of IGFBP5 in a HIF1-dependent manner. Once secreted, IGFBP5 functions, in parallel to other intracellular branches of the feedback mechanisms, to block the function of IGF-1 (Fig. 5) . IGFBP5 is a potential tumour suppressor, and the proliferation of IGFBP5-mutated cells is sensitive to IGF-1R inhibitors. Finally, our results raise an intriguing hypothesis that IGFBP5 might serve as a 'non-cell autonomous' feedback mechanism for tumours to restrain IGF-1R signalling in adjacent normal cells. In so doing, tumour cells might gain a competitive advantage in growth and proliferation. Whether this mechanism contributes to tumour progression warrants further investigation. Supplementary Fig. 6 . 
METHODS
Methods and any associated references are available in the online version of the paper. Sample preparation for mass spectrometric analysis. SILAC-labelled TSC2 −/− MEFs were serum-deprived for 24 h, during which cells cultured in light media were treated with 20 nM rapamycin. Conditioned medium (CM) was collected, which was centrifuged at 1,500 r.p.m. (239g ) for 15 min to remove residual cells. The CM samples were further filtered through 0.45 µm filters.
The light and heavy CM were combined at a 1:1 ratio (normalized by cell lysates), and then concentrated by a Centricon ultrafiltration unit (Millipore, MWCO = 5,000 Da). Proteins were extracted by methanol-chloroform precipitation, and were then solubilized in 8 M urea. Cysteines were reduced by 2 mM dithiothreitol, and were then alkylated by adding iodoacetamide to a final concentration of 50 mM, followed by incubation in the dark for 20 min. The lysates were diluted to a final concentration of 2 M urea by addition of 100 mM ammonium bicarbonate (pH 7.8) and were digested overnight with sequencing-grade trypsin (Promega) at a 1:100 (enzyme/substrate) ratio. Digestion was quenched by addition of trifluoroacetic acid to a final concentration of 0.1% and precipitates were removed by centrifugation at 4,000 r.p.m. (1,699g ) for 30 min. Peptides were desalted using SepPak C18 columns (Waters) according to the manufacturer's instructions.
Peptides were fractionated by using an off-line two-dimensional SCX-RP-HPLC (strong-cation-exchange reversed-phase HPLC) protocol 37 . Briefly, lyophilized peptides were resuspended in 500 µl SCX buffer A (5 mM KH 2 PO 4 , pH 2.65, 30% acetonitrile) and injected onto a SCX column (polysulphoethyl aspartamide, 4.6 mm × 200 mm, 5 µM particle size, 200Ǻ pore size, PolyLC). A gradient was developed over 35 min ranging from 0 to 21% buffer B (5 mM KH 2 PO 4 , pH 2.65, 30% acetonitrile, 350 mM KCl) at a flow rate of 1 ml min −1 . Twelve fractions were collected and lyophilized. Peptides were then desalted using SepPak C18 columns and lyophilized. In the second dimension, peptides were separated on a 75 µm × 15 cm in-house packed RP column (Maccel 200-3-C18AQ, 3 µm, 200 Å) using a gradient developed over 90 min ranging from 0% to 37% buffer B (97% acetonitrile, 0.1% formic acid). Peptides were directly introduced into the mass spectrometer using a hand-pulled emitter.
Mass spectrometry analysis and data processing. The SILAC sample was analysed by LC-MS/MS experiments on an LTQ Velos Pro Orbitrap mass spectrometer (Thermo) using a top-20 CID (collision-induced dissociation) method 38 . MS/MS spectra were searched against a composite database of the mouse IPI protein database (Version 3.60) and its reversed complement using the Sequest algorithm. Search parameters allowed for a static modification of 57.02146 Da for cysteine and a dynamic modification of oxidation (15.99491 Da) on methionine, stable isotope (10.00827 Da) and (8.01420 Da) on arginine and lysine, respectively. Search results were filtered to include <1% matches to the reverse database by the linear discriminator function using parameters including Xcorr, dCN, missed cleavage, charge state (exclude 1+ peptides), mass accuracy, all heavy or light Lys and Arg, peptide length and fraction of ions matched to MS/MS spectra 39 . Peptide quantification was performed by using the CoreQuant algorithm 39 . As serum proteins are always light (residual proteins from FBS), we further removed the peptides in which only the light ion is present (the signal-to-noise ratio of the heavy peptide equals zero). A step-by-step protocol of the mass spectrometry analysis can be found at Nature Protocol Exchange 40 . From this SILAC CM sample, we identified and quantified a total of 61,920 peptides from 3,099 proteins (peptide false discovery rate = 0.27%; Fig. 1d and Supplementary Tables 4-7) . We sorted the proteins on the basis of their number of identified peptides. The top five proteins are fibronectin, plectin-1, collagen alpha-2(I) chain, filamin-A and collagen alpha-1(I) chain, all of which are known secreted or membrane-bound proteins. These proteins were confidently identified, with sequence coverage of 64.8%, 52.8%, 87.7%, 66.1% and 81.8%, respectively. The list also contains many secreted proteins that are known to be expressed at low abundances, including chemokines (CCL2, CCL7, CCL9, CXCL1, CXCL5 and CXCL16) and growth factors (TGFB2, TGFB3, HDGF and CTGF). The identification of these extracellular signalling molecules demonstrates the excellent sensitivity of our MS method.
We also performed a biological replicate SILAC experiment (SILAC experiment no. 2) with switched isotope labels (that is, heavy cells treated with rapamycin). In this experiment, we identified 3,927 proteins from the CM of TSC2 −/− MEFs. In total, we identified 4,195 unique proteins from these two sets of SILAC CM samples. Cross-reference analysis indicates that 2,825 proteins were commonly identified between the two SILAC experiments, yielding a reproducibility of 71.9% (Supplementary Fig. 1D ).
As rapamycin treatment abrogated the expression of the IGF-1-inhibitory protein (Fig. 1a) , we focused our follow-up analysis on proteins whose abundances decreased as a result of mTORC1 inhibition. Gene ontology (cellular compartment) analysis of these proteins showed that they were highly enriched for extracellular matrix proteins (P = 6.5 × 10 −10 ; Supplementary Fig. 2A ). Furthermore, we submitted this group of proteins, and compared them with the human Plasma Proteome Database 41 . The results show that of the 355 proteins, 301 (84.8%) have been found previously in plasma, again highlighting that this list is enriched with extracellular proteins. mTOR inhibitor treatment. Inhibition of mTORC1 in TSC2 −/− MEFs by either rapamycin or mTOR kinase inhibitors (Ku0063794 and NVP-BEZ235 42 ) resulted in a marked decrease of IGFBP5 (Fig. 1f-h ). In contrast, treatment of these cells with an S6K inhibitor, PF-4708671 (ref. 26) , had no effect on IGFBP5 levels (Fig. 1h) . These results indicate that mTORC1 itself, rather than S6K, regulates the expression of IGFBP5. We also show that mTORC1 regulates the expression of IGFBP5 in other cell lines. Specifically, rapamycin treatment of RT-4 cells (a TSC1-deficient bladder cancer cell line 43 ) also resulted in marked reduction of the abundance of secreted IGFBP5 (Supplementary Fig. 1H ). To investigate whether mTORC1 is involved in regulating the expression of IGFBP5 in TSC1/2-proficient cells, we starved MCF7 cells and then stimulated them with insulin. We found that this treatment led to robust accumulation of IGFBP5 in CM, which was strongly suppressed when cells were concurrently treated with rapamycin ( Supplementary Fig. 1I ).
Plasmids. The cDNA for human and mouse IGFBP5 was obtained from Invitrogen, amplified by PCR, and cloned into a pKH3 vector. Cancer-associated IGFBP5 mutants were generated using the QuickChange site-directed mutagenesis kit (Stratagene). Lentiviral plasmids (∆8.9 and VSVG) were kind gifts from A. Kung (Dana Farber Cancer Institute, USA) and D. Baltimore (California Institute of Technology, USA).
Mammalian lentiviral shRNAs. Lentiviral short hairpin RNA (shRNA) in pLKO.1 expression vectors were obtained from Sigma. The shRNA sequences are listed in Supplementary Table 9 . To generate the lentiviruses, shRNA plasmids were co-transfected into HEK293TD cells along with packaging (∆8.9) and envelope (VSVG) expression plasmids using Lipofectamine 2000 (Invitrogen). Two days after transfection, viral supernatants were collected and filtered. Recipient cells were infected in the presence of a serum-containing medium supplemented with 8 µg ml −1 Polybrene. Following infection for 36 h, cells were treated with 2.0 µg ml −1 puromycin (Sigma) and cell lines that stably expressed the shRNAs were selected. Knockdown efficiencies were examined by immunoblot assay using antibodies against the target protein.
Depletion of IGFBP5 sensitizes TSC2 −/− MEFs to IGF-1 stimulation. Specifically, TSC2 −/− MEFs exhibited a profound 'IGF-1-resistant' state, as indicated by the lack of IGF-1R activation, on IGF-1 stimulation (Fig. 3b) . Intriguingly, RNAimediated knockdown of IGFBP5 in TSC2 −/− MEFs greatly sensitizes them to IGF-1 stimulation (Fig. 3b) . Using a quantitative ELISA approach, we determined the concentration of IGFBP5 in CM of TSC2 −/− MEFs (starved for 24 h at 90% confluency) to be about 300 ng ml −1 . For 40 ng ml −1 of IGF-1, this translates into a molar ratio between IGFBP5 and IGF-1 of ∼4:1. We have also found this medium is able to inhibit up to 80 ng ml −1 of IGF-1 (2:1 between IGFBP5 and IGF-1; not shown). These IGFBP5 concentrations and IGFBP5/IGF-1 ratios are in fact close to those in serum samples from rats and humans 44, 45 .
Immunoblot analysis. For immunoblot analysis, the cells were extracted in lysis buffer (20 mM HEPES pH 7.5, 1% Triton X-100, 150 mM NaCl, 10 mM EDTA, 1 mM EGTA, 1 mM sodium orthovanadate, 1 mM NaF, 2 mM phenylmethylsulphonyl fluoride, 2 mg ml −1 aprotinin, 2 mg ml −1 leupeptin, and 1 mg ml −1 pepstatin), and extracts were mixed with the 5× reducing buffer (60 mM Tris-HCl, pH 6.8, 25% glycerol, 2% SDS, 14.4 mM 2-mercaptoethanol, 0.1% bromophenol blue). Samples were boiled for 5 min and subject to electrophoresis using the standard SDS-PAGE method. Proteins were then transferred to a nitrocellulose membrane (Whatman). The membranes were blocked with a TBST buffer (25 mM Tris-HCl, pH 7.5, 150 mM NaCl, 0.05% Tween 20) containing 3% non-fat dried milk, and probed overnight with primary antibodies (1:1,000 dilution) at 4 • C and for 1 h at room temperature with peroxidase-conjugated secondary antibodies. Blots were developed using enhanced chemiluminescence, exposed on autoradiograph film and developed using standard methods. Western blot images were quantified by using the software package ImageJ. Luciferase reporter assay. The pGL4.42 (luc2P/HRE/Hygro) vector (Promega) containing four copies of HRE was used as the positive control in the luciferase reporter assay. To explore the potential HRE sites in the IGFBP5 gene, fragments of IGFBP5 that are upstream and downstream of the genomic transcription start site were amplified and were used to substitute the HRE site between the XhoI and KpnI sites in the pGL4.42 vector. Four reporter vectors were generated with this strategy, pGL4.P1 (P1, −1.5 kb ∼ −50 bp), pGL4.P2 (P2, −0.6 kb ∼ −50 bp), pGL4.P3 (P3, +0.1 kb ∼ +0.9 kb), pGL4.P4 (P4, +2.9 kb ∼ +3.2 kb). The sequences of the primers and the relative distance from the IGFBP5 transcription start site are listed in Supplementary Table 2 . To perform the luciferase reporter assay, these pGL4 reporter vectors were co-transfected with pcDNA3.1-HIF1α or pcDNA3.1 empty vector into HEK293T cells. The pGL4-hRluc expressing the Renilla reniformis luciferase under the TK promoter was used as the internal control in each experiment. Forty-eight hours after transfection, cells cultured in either normoxic or hypoxic (1% O 2 ) conditions were collected and were used to determine the luciferase activity using the protocol from Promega. Experiments were performed in triplicate.
Chromatin immunoprecipitation (ChIP). Two 15 cm plates of RT4 cells (70% confluency) were used for the ChIP experiment after overnight incubation in hypoxic (1% O 2 ) conditions. The medium was removed and 1% paraformaldehyde (Thermo Fisher Scientific) in PBS was added into the culture plate. The plates were slowly shaken for 10 min at room temperature, and the crosslinking reagent was quenched with 1 ml 2.5 M glycine. The crosslinked cells were collected with cell lysis buffer (10 mM HEPES, pH 8.0, 85 mM KCl, 0.5% NP-40). Crude nuclear pellets were treated with 50 U MNase for 1 h on ice. EDTA was added to a final concentration of 50 mM to inactivate MNase. After centrifugation, nuclear extracts (dissolved in the nuclei extraction buffer, 50 mM Tris-HCl, pH 8.0, 10 mM EDTA, 1% SDS) were sonicated on ice until the size of the fragmented DNA reached between 300∼1,000 bp. Fragmented chromatin was diluted with 10 volumes of dilution buffer (50 mM Tris-HCl, pH 8.0, 10 mM EDTA) for the ChIP experiments. ChIP was performed using an anti-HIF1α (Bethyl Laboratories) antibody and normal IgG (Santa Cruz Biotechnology) was used as the control. The genomic DNA recovered from ChIP was analysed by real-time qPCR using primers specific to the −1.5 kb, −0.5 kb, and +3.0 kb region of the IGFBP5 promoter. Experiments were performed in triplicate.
Statistics and repeatability of experiments.
All immunoblotting experiments were independently repeated at least three times. Quantification and statistical data processing were performed by using ImageJ and GraphPad Prism, respectively. The results for significance tests are included in the legend of each figure. The qPCR experiments in Fig. 2g ,h were performed with RNA prepared from three independent biological replicate experiments. The luciferase reporter assays in The results were quantified using ImageJ. For site-specific phosphorylation, pIGF-1R(Y1135/1136), pAkt(S473) and pS6K(T389) levels were analyzed. pIGF-1R levels were normalized using total IGF-1R levels (note the rapamycin treatment increases total IGF1-R levels). **P < 0.01 (two-tailed Student t-test), NS=Not significant. n = 4 independent biological replicate experiments. Error bars represent s.d. Supplementary Figure 6 continued 
